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MAGE-A antigens belong to cancer/testis (CT) antigens that are expressed in tumors but not in normal tissues except testis and
placenta. MAGE-A antigens and their epitope peptides have been used in tumor immunotherapy trials. MAGE-A4 antigen is
extensively expressed in various histological types of tumors, so it represents an attractive target for tumor immunotherapy. In
this study, we predicted HLA-A∗0201-restricted cytotoxic T lymphocyte (CTL) epitopes of MAGE-A4, followed by peptide/HLA-
A∗0201 aﬃnity and complex stability assays. Of selected four peptides (designated P1, P2, P3, and P4), P1 (MAGE-A4286−294,
KVLEHVVRV) and P3 (MAGE-A4272−280, FLWGPRALA) could elicit peptide-speciﬁc CTLs both in vitro from HLA-A∗0201-
positive PBMCs and in HLA-A∗0201/Kb transgenic mice. And the induced CTLs could lyse target cells in an HLA-A∗0201-
restricted fashion, demonstrating that the two peptides are HLA-A∗0201-restricted CTL epitopes and could serve as targets for
therapeutic antitumoralvaccination.
1.Introduction
The melanoma antigen genes family A (MAGE-A) consists
of 12 closely related genes (MAGE-A1 to A12) located in
the q28 region of chromosome X [1, 2]. MAGE-A-encoded
antigens (MAGE-A) belong to cancer/testis (CT) antigens.
These antigens are expressed in various histological types of
carcinomas, but not in normal tissues with the exception of
testis and placenta [3–8]. Although testis expresses MAGE-
A antigens and placenta also expresses some of them [9],
testis and placenta do not express MHC class I molecules
and therefore cannot be attackedby cytotoxicTlymphocytes
(CTLs) speciﬁc for these antigens. Thus, MAGE-A antigens
are appealing targets for antitumor immunotherapy. A
number of clinical trials of therapeutic vaccination have
been performed, based on these antigens and their epitope
peptides. In some clinical trials executed with short peptides,
tumor regressions have been observed in a minority of
patients [10–12].
Of the MAGE-A family, MAGE-A4 is one of genes that
are abundantly expressed by many tumors of diﬀerent
histological types, such as urothelial carcinoma, bladder
cancer, lung cancer, ovarian neoplasm, esophageal squamous
cell carcinoma, and oral squamous cell carcinoma [4, 13–
17]. Up to now, at least four variants have been found for
this gene. The four variants encodethe same proteinreferred
to MAGE-A4. MAGE-A4 is found to interact with the liver
oncoprotein gankyrin and suppress the tumorigenic activity
of gankyrin [18]. Its carboxyl-terminal fragment of 107
amino acids induces p53-dependent and p53-independent
apoptosis in human cells [19]. Moreover, the expression
of MAGE-A4 may increase caspase-3 activity and promote
tumor cell death [14].
Recent studies have identiﬁed several antigenic peptides
presented by HLA class I molecules, including HLA-A24
restricted MAGE-A4143–151 (NYKRCFPVI)peptide, HLA-A1
restricted MAGE-A4169–177 (EVDPASNTY) peptide, HLA-
B37 restricted MAGE-A4156–163 (SESLKMIF) peptide, and
HLA-A∗0201 restricted MAGE-A4230–239 (GVYDGREHTV)
peptide [20–23]. It is reported that a polyepitope vaccine
targeted to one antigen may elicit strong antigen-speciﬁc
CTLs to protect against tumor challenge and almost each2 Clinical and Developmental Immunology
epitope in the polyepitope can induce speciﬁc CTL immune
response [24, 25]. On the other hand, about 50% of
Caucasians and Asians express HLA-A∗0201 [23]. So the
identiﬁcation of more HLA-A∗0201-restricted epitopes for
MAGE-A4 is likely to provide alternative candidates for the
future of clinical trials with deﬁned antigenic peptides and
facilitate the design of antitumor vaccines with high eﬃcacy.
To identify epitopes capable of inducing MAGE-A4-
speciﬁc HLA-A∗0201-restricted CTLs, we ﬁrst predicted
HLA-A∗0201-restricted epitopes of MAGE-A4 and mea-
sured HLA-A∗0201 binding capacity of the candidate epi-
tope peptides. We then induced MAGE-A4-speciﬁc CTLs
from HLA-A∗0201 peripheral blood mononuclear cells
(PBMCs)with thesecandidate peptidestoseek CTL epitopes
from MAGE-A4 antigen, followed by validation for in vivo
immunogenicity.
2.MaterialandMethods
2.1. Cell Lines and Animals. The HLA-A∗0201-expressing
human tumor cells T2 (deﬁcient in TAP1 and TAP2 trans-
porters), MCF-7 (breast cancer; MAGE-A-negative [26]),
and BB7.2 hybridoma producing anti-HLA-A2 monoclonal
antibody (mAb) were purchased from American Type
Culture Collection (ATCC, USA). Human melanoma cells
LB1751-MEL expressing MAGE-A and HLA-A∗0201 were
kindly provided by Dr. F. Brasseur (Ludwig Institute for
Cancer Research, Brussels, Belgium).
HLA-A∗0201/Kb transgenic mice (6–8 weeks old) were
purchased from the Jackson Laboratory (USA). Animal
experiments were performed in accordance with the guide-
lines of the Animal Care and Use Committee of Third
Military Medical University.
2.2. Epitope Prediction and Peptide Synthesis. The MAGE-A4
protein sequence was analyzed for 9-amino acid long pep-
tides, which could potentially bind to HLA-A∗0201 mole-
cule, using the computer-based epitope prediction programs
BIMAS (http://www-bimas.cit.nih.gov/molbio/hla bind/in-
dex.shtml)an dSY FP EITHI(http://www.syfpeithi.de/Scripts/
MHCServer.dll/EpitopePrediction.htm). The selected can-
didate peptides and control peptides (HBcAg18–27 and
OVA257–264) were synthesized by Fmoc chemistry (Sangon,
China) and puriﬁed by HPLC to a purity of >95%.
2.3. Aﬃnity Measurement of Peptide for HLA-A∗0201. The
aﬃnity of peptides for HLA-A∗0201 was measured as
described previously [27]. Brieﬂy, T2 cells were incubated
with various concentrations of each peptide and 3μg/mL
human β2m in serum-free RPMI 1640 medium at 37◦Cf o r
16h. Then, the cells were washed and stained with antiHLA-
A2 mAb and FITC-labeled goat anti-mouse IgG. The expres-
sion of HLA-A∗0201 on T2 cells was determined with FACS
Calibur ﬂow cytometer (Becton Dickinson, USA). For each
peptide concentration, the percent mean ﬂuorescence index
(% MFI) increase of HLA-A∗0201 molecule was calculated
as follows: % MFI increase = [(MFI with the given peptide −
MFI without peptide)/(MFI without peptide)] × 100.
2.4.AssessmentofPeptide/HLA-A∗0201ComplexStability. As
previously described [28], T2 cells (106/mL) were incubated
overnight with 100μM of each peptide in serum-free RPMI
1640 medium supplemented with 100ng/mL human β2m
at 37◦C. Then, they were washed to remove free peptides
and incubated with 10μg/mL of BrefeldinA (Sigma-Aldrich,
USA) for 1h to block newly synthesized HLA-A∗0201
molecules to be expressed on cell surface, washed and
incubated at 37◦C for 0, 2, 4, 6, or 8h. Subsequently, the
cells were stained with the anti-HLA-A2 mAb to evaluate the
expression of HLA-A∗0201 molecules.
2.5. Plasmid Construction and Cell Transfection. The mam-
malian expression plasmid pCI-MAGEA4, which contains
the encoding sequence of MAGE-A4, was constructed as
described below. Total RNA was extracted from LB1751-
MEL cells using TRIZOL reagent (Invitrogen, USA). First-
strand cDNAwas synthesized and PCR was performed using
High Fidelity PrimeScript RT-PCR Kit (TaKaRa, Dalian,
China) and primers (forward, 5 -TGCCCTGACCAGAGT-
CATCAT-3 ;r e v e r s e ,5  -ACAGAGTGAAGAATGGGCCT-
3 ), accordingto themanufacturer’s instructions. The ampli-
ﬁed productswere inserted intopMD18-T plasmid (TaKaRa,
Dalian, China) and the plasmid cloned into cDNA sequence
of MAGE-A4 was selected and identiﬁed by restriction
endonucleasedigestionandsequencing.Andthentheencod-
ing sequence of MAGE-A4 was ampliﬁed from the selected
plasmid above and cloned into Nhe I/Mlu I sites of pCI-
neo plasmid (Promega, Beijing, China) using primers 5 -
TCTAGCTAGCATGTCTTCTGAGCAGAAGAGTCAGC-3 
(forward) and 5 -CCTACGACGCGTTCAGACTCCCTC-
TTCCTCCTCTAAC-3  (reverse).
To establish a cell line expressing both HLA-A∗0201 and
MAGE-A4, MCF-7 cells were transfected with plasmid pCI-
MAGEA4 using Lipofectamine 2000 (Invitrogen, USA) and
then selected with G418. The expression of MAGE-A4 in the
establishedcellline(designatedMCF-7A4)wasconﬁrmedby
reverse transcription-PCR and western blotting.
2.6. Induction of CTLs from Human PBMCs. PBMCs were
isolated from the buﬀy coat of heparinized whole blood
samples of healthy HLA-A∗0201 donors by density gra-
dient centrifugation on the Ficoll-Paque PREMIUM (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden). The eﬀector
lymphocytes and dendritic cells (DCs) were prepared by our
published method [29]. All donors signed written, informed
consent to provide whole blood samples used in the study.
Approval of the study was obtained from the relevant ethical
committees and was in accordance with the Declaration of
Helsinki.
2.7. Cytotoxicity Assay. Three to ﬁve days after the ﬁnal
stimulation, the cytotoxic activity of the eﬀector cells
was evaluated by a lactate dehydrogenase release assay
using Cytotox 96 Non-Radioactive Cytotoxicity Assay kit
(Promega, USA) [30]. In brief, 1 × 104 target cells (LB1751-
MEL, MCF-7 or MCF-7A4) in 50μL RPMI 1640 containing
5% fetal calf serum (FCS)was placed in the wells ofa 96-wellClinical and Developmental Immunology 3
round-bottom plate, then 50μL of various concentrations of
eﬀector cells was added at diﬀerent eﬀector to target (E/T)
ratios (50/1, 25/1, and 12.5/1). After 4 h incubation at 37◦C,
the supernatant was collected to assay lactate dehydrogenase
(LDH) release by OD490 measurement according to the
manufacturer’s instructions. Experiments were performed in
t r i p l i c a t e sa n dt h ep e r c e n t a g eo fl y s i sw a sc a l c u l a t e da s%
Lysis = [(experimental LDH release − eﬀector spontaneous
LDH release − target spontaneous LDH release)/(target
maximum LDH release − target spontaneous LDH release)]
× 100.
2.8. Analysis of In Vivo Immunogenicity. HLA-A∗0201/Kb
mice were immunized with 100μg of various peptides pre-
pared in IFA or IFA emulsion without peptide as a control.
After 10 days, mice were sacriﬁced and splenocytes were
cultured for 5 days with 10units/mL recombinant murine
interleukin-2 (rmIL-2) and 2μg/mL peptide. And then,
eﬀector cells were counted and tested for cytotoxic activity
in a cytotoxicity assay.
2.9. Statistical Analysis. Statistical analyses were performed
using the variance test and Student’s t-test. A diﬀerence was
considered signiﬁcant at the conventional level of P<. 05.
3.Results
3.1. Prediction of HLA-A∗0201-Restricted CTL Epitopes. The
HLA-A∗0201-restricted CTL epitopes of MAGE-A4 were
predicted using BIMAS software. The top four ranking
peptides with BIMAS scores were selected and then veriﬁed
using the program SYFPEITHI. As shown in Table 1, all of
the four peptides had high SYFPEITHI scores. Thus, they
were selected as the candidate eptitope peptides.
3.2. Aﬃnity of Candidate Epitope Peptides for HLA-A∗0201
Molecule. We then evaluated the binding aﬃnity of these
candidate epitope peptides for HLA-A∗0201 molecule in
vitro using a T2-cell-peptide binding test. Figure 1 showed
that P3 had highest aﬃnity for HLA-A∗0201 molecule and
P2 was lower aﬃnity peptide, while P1 and P4 had lowest
aﬃnity. The negative control peptide did not increase the
expression of HLA-A∗0201 molecule on the T2 cell surface
at all indicated peptide concentrations.
Because a stable peptide-MHC complex is very impor-
tant for the induction of an antigen-speciﬁc CTL immune
response [29, 31, 32], we further investigated the capacity
of candidate epitope peptides to stabilize the HLA-A∗0201
molecule (Table 2). The results indicated that P3 exhibited
highest stabilization capacity (DC50> 8h)andP4wasweak
stabilizer of HLA-A∗0201 molecule (DC50< 2h). P2 had
ab i n d i n ga ﬃnity higher than that of P1 (Figure 1), but
P2 stabilized HLA-A∗0201 molecule more weakly than P1
(DC50< 2hand4–6h,resp.).
3.3. In Vitro Induction of Peptide-Speciﬁc CTLs. To study
whether these candidate epitope peptides can induce the
generation of peptide-speciﬁc CTLs in vitro,P B M C sf r o m
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Figure 1: Binding aﬃnity of peptides for HLA-A∗0201 molecule.
T2 cells were incubated with indicated concentrations of the
peptides in serum-free RPMI 1640 medium supplied with 3μg/mL
human β2m at 37◦C for 16h. And then the cells were stained
with anti-HLA-A2 mAb andFITC-labeled goat antimouseIgG. The
expression of HLA-A∗0201 on T2 cells was determined with FACS
Calibur ﬂow cytometer. The peptides HBcAg18–27 and OVA257–264
were taken as positive control and negative control, respectively.
Each sample was measured in three replicates and the experiment
was repeated three times.
3H L A - A ∗0201 individuals were prepared and stimulated
with peptide-pulsed autologous DCs and PBMCs succes-
sively. The cytotoxic activity of the stimulated PBMCs
(eﬀector cells) was evaluated using a cytotoxicity assay.
The data from one representative donor was shown in
Figure 2. The results showed that P1 and P3-stimulated
PBMCs could signiﬁcantly lyse the target cells LB1751-
MEL. However, similar to the irrelevant peptide HBcAg18–27,
P2- and P4-stimulated PBMCs could not lyse the target
cells (Figure 2(a)). After blocking HLA-A∗0201 molecules
on the surface of LB1751-MEL cells with anti-HLA-A2
mAb, the lysis of LB1751-MEL cells by the eﬀector cells
was signiﬁcantly abrogated (Figure 2(b)). Moreover, P1-
and P3-primed eﬀector cells could also lyse MCF-7A4 cells
expressing both HLA-A∗0201 and MAGE-A4 (Figure 2(c)),
but not MAGE-A4-negative MCF-7 cells (Figure 2(d)). The
similarresultswereobtainedwhentheothertwodonorswere
tested with these peptides (data not shown).
3.4. In Vivo Induction of Peptide-Speciﬁc CTLs in HLA-
A∗0201/Kb Transgenic Mice. Finally,we investigatedwhether
the peptides P1 and P3 could also elicit CTL immune
responses in vivo.TheHLA -A ∗0201/Kb transgenic micewere
inoculated once with the two peptides, respectively. Ten
days later, the splenocytes were harvested and stimulated in
vitro with the corresponding peptide. The cytotoxicity assay
showed that the splenocytes from the P1- and P3-inoculated
mice couldlyse target cells LB1751-MEL, butthe splenocytes
from the IFA-inoculated mice could not lyse the target cells
after stimulated in vitro with P1 or P3. When anti-HLA-A24 Clinical and Developmental Immunology
Table 1: Predicted HLA-A∗0201-restricted CTL epitopes by BIMAS and SYFPEITHI methods.
Peptide Sequence Position BIMAS SYFPEITHI
Score Rank Score Rank
P1 KVLEHVVRV 286–294 743 1 25 4
P2 ALLEEEEGV 309–317 517 2 27 3
P3 FLWGPRALA 272–280 189 3 21 9
P4 ALPTTISFT 71–79 94 4 20 10
Table 2: HLA-A∗0201 stabilization capacity of candidate epitope peptides.
Peptide % MFI increase at indicated time point (h) DC50
a
0246 8
P1 126.16 95.74 74.98 60.29 49.07 4–6
P2 170.07 84.13 57.09 42.34 31.19 <2
P3 285.66 230.85 192.71 170.05 150.56 >8
P4 98.80 48.73 30.79 21.01 18.52 <2
HBcAg18–27 243.26 194.51 161.13 148.39 131.08 >8
(a)Half-time of the peptide/HLA-A∗0201 complex.
mAb was added, anti-HLA-A2 mAb inhibited the peptides-
induced splenocytes from killing the targets (Figure 3).
4.Discussion
Tumor-speciﬁc immunotherapy is an appealing strategy in
treating tumors. The identiﬁcationof tumor-associated anti-
gens (TAAs) and their epitopes has boosted the development
of the strategy. TAAs are composed of ﬁve major groups:
cancer/testis (CT) antigens (e.g., MAGE, BAGE, GAGE, NY-
ESO-1, and SSX [33–35]), mutated antigens (e.g., MUM-1,
p53, and beta-catenin [36, 37]), overexpressed antigens (e.g.,
RCAS1, Survivin, and Her2/neu [38–40]),oncofetal antigens
(e.g., Immature laminin receptor and CEA [41, 42]), and
diﬀerentiation or lineage antigens (e.g., tyrosinase, Melan-
A/MART-1, gp100, TRP-1, and TRP-2 [43, 44]). Because
CTLs play a key role in antitumor immune responses [45]
and CT antigens are expressed in many tumors but not in
normaltissues excepttestisandplacenta,theidentiﬁcationof
CTL epitopesderivedfrom CTantigensisvery important for
the studies of antitumor vaccines based on deﬁned epitope
peptides.
In this study, we predicted the HLA-A∗0201-restricted
CTL epitopes of the tumor antigen MAGE-A4 with a com-
bination of BIMAS and SYFPEITHI programs and selected
four peptides (P1, P2, P3, and P4) as candidates based
on immunogenicity score. Then we examined the binding
aﬃnity ofthesepeptidesforHLA-A∗0201andpeptide/HLA-
A∗0201 complex stability. The results showed that P3 had
both highest binding aﬃnity for HLA-A∗0201 and strongest
capacity of stabilizing complex among the four peptides.
P2 had intermediate binding aﬃnity, but it exhibited weak
stabilization capacity. On the other hand, P1 bound weakly
to HLA-A∗0201 molecules, but it could form more stable
complexes with HLA-A∗0201 molecules than P2 and P4.
Recent studies indicate that peptide/MHC complex stability
is an important parameter for distinguishing immunogenic
peptides from nonimmunogenic peptides, and that a stable
peptide/MHC complex may facilitate the formation of the
synapses betweenTcellsand antigen-presenting cells(APCs)
and warrant the full T cell activation through sustained
signaling [28, 31, 32, 46]. Our data suggested that P1 and P3
could be promising epitope candidates.
An in vitro CTL induction assay conﬁrmed that P1
and P3 could eﬀectively prime peptide-speciﬁc CTLs that
could lyse HLA-A∗0201+MAGE-A4+ target cells in an
HLA-A∗0201-restricted fashion, but P2- and P4-stimulated
PBMCs could not lyse the target cells. At the same time,
P1- and P3-stimulated PBMCs could also lyse the HLA-
A∗0201+ MCF-7A4 cells transected with MAGE-A4 gene but
not MAGE-A4-negative MCF-7 cells. The in vivo immuno-
genicity analysis found that P1 and P3 could also induce
speciﬁc CTLimmune responses in vivo.These datashow that
P1 and P3 are HLA-A∗0201-restricted CTL epitopes and the
two peptides can induce peptide-speciﬁc CTLs both in vitro
and in vivo which recognize endogenouslyprocessed MAGE-
A4 antigen.
Noticeably, by aligning the sequences of MAGE-A, we
found that P3 (FLWGPRALA) is shared by MAGE-A1, -A4,
and -A8 and that P3 is highly homologous to two peptides
FLWGPRALI (shared by MAGE-A2 and -A6) and FLWG-
PRALV (shared by MAGE-A3 and -A12)with just one amino
acid diﬀerent at the carboxyl-terminus. It has been reported
that the interaction between epitope peptide and MHC class
I molecule mainly depends on anchor residues P2 and P9 in
the nonapeptide, and the P3–P8 segment of the nonapeptide
epitope contributes to the peptide/TCR interaction [28, 47–
49]. The peptide FLWGPRALV is a known HLA-A∗0201
restricted epitope of MAGE-A3, but it is not eﬃciently pro-
cessed by tumor cells[50]. Therefore, we guess that P3 might
be a common HLA-A∗0201-restricted CTL epitope among
most of MAGE-A family members and have a potential
application in peptide-mediated immunotherapy, because
above 80% of all tumors express at least one MAGE-AClinical and Developmental Immunology 5
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Figure 2: Induction of peptide-speciﬁc CTLs from human PBMCs. PBMCs from healthy HLA-A∗0201 donors were ﬁrst stimulated
with peptide-pulsed autologous DCs and then restimulated with peptide-pulsed autologous PBMCs. After three to ﬁve days of the ﬁnal
stimulation,the stimulated PBMCs were used as eﬀector cells to detect their cytotoxic activity against tumor cells at the indicated E/T ratios
in a cytotoxicity assay. The irrelevant peptide HBcAg18–27 was taken as negative control. Each sample was measured in three replicates and
the experiment was repeated three times. (a) P1, P2, P3, and P4-stimulated PBMCs mediated lysis of LB1751-MEL cells. (b) P1- and P3-
stimulated PBMCs mediated lysis of LB1751-MEL cells (P1 and P3) and LB1751-MEL cells which surface HLA-A∗0201 molecules were
blocked with ant- HLA-A∗0201 mAb (P1 + HLA-A2 mAb and P3 + HLA-A2 mAb). (c) P1- and P3-stimulated PBMCs mediated lysis of
MCF-7A4 cells. (d) P1- and P3-stimulated PBMCs mediated lysis of MCF-7 cells.
antigen. In addition, the P1 epitope (KVLEHVVRV) is
shared by MAGE-A4 and MAGE-A8. The peptide seems to
have homology to the HLA-A∗0201-restricted CTL epitope
MAGE-A1278–286 (KVLEYVIKV) [51], but the two epitopes
exist TCR ligand sequencedissimilarity with diﬀerenceat the
P5,P7,andP8residues.Itremains unclearifthetwoepitopes
KVLEHVVRV and KVLEYVIKV have the same speciﬁcity.
In conclusion, our results demonstrate that P1 (MAGE-
A4286–294, KVLEHVVRV) and P3 (MAGE-A4272–280,
FLWGPRALA) derived from MAGE-A4 are HLA-A∗0201-
restricted CTL epitopes, which can be endogenously
presented to the surface of HLA-A∗0201+MAGE-A4+ tumor
cells. The identiﬁcation of the two epitopes might provide
alternative candidates for the studies of tumor-therapeutic
vaccines based on deﬁned antigenic peptides. Currently, we
are investigating if P3-stimulated PBMCs can also recognize
and kill the HLA-A∗0201+ tumor cells expressing one of
other members of MAGE-A family.6 Clinical and Developmental Immunology
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Figure 3: In vivo induction of peptide-speciﬁc CTLs. The HLA-
A∗0201/Kb transgenic mice were immunized with the peptides
P1 and P3 prepared in IFA, respectively. Another group of mice
were immunized with IFA without peptide as negative control.
Mice were sacriﬁced 10 days after immunization and splenocytes
were stimulated in vitro for 5 days with 2μg/mL peptide and
10units/mL rmIL-2 to expand them as eﬀector cells. A cytotoxicity
assaywasused to evaluatethe lysisofLB1751-MEL cells by peptide-
stimulated splenocytes from corresponding peptide-immunized
mice (P1 and P3), P1- or P3-stimulated splenocytes from IFA-
immunized mice (IFA+P1 and IFA+P3), and the lysis of LB1751-
MELcells,whichsurfaceHLA-A∗0201moleculeswereblockedwith
ant-HLA-A∗0201mAb,bypeptide-immunized mice(P1+HLA-A2
mAb and P3 + HLA-A2 mAb). The experiment was repeated three
times.
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